Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.

The oxygen status of skin is a controversial topic. Skin is radiosensitive, suggesting it is well-oxygenated. However, it can be further sensitized with nitroimidazole drugs, implying that it is partially hypoxic. Skin oxygen levels are difficult to measure with either electrodes or the hypoxia-monitoring agent (3)H-misonidazole. For the latter, binding has previously been reported to be high in murine skin, but this could be attributed to either non-oxygen-dependent variations in nitroreductase activity, drug metabolism, and/or actual oxygen gradients. We obtained tumor and skin from patients given EF5, a 2-nitroimidazole tissue hypoxia monitor. We performed immunohistochemical studies using highly specific monoclonal antibodies for the hypoxia-dependent production of EF5 tissue adducts. Some tissue sections were counterstained using either Ki67 for proliferation or CD31 for vessels. We found that the human dermis is well-oxygenated, the epidermis is modestly hypoxic and portions of some sebaceous glands and hair follicles are moderately to severely hypoxic. Normal and irradiated skin had similar oxygenation patterns. Control studies demonstrated that these observations are not due to tissue variations in nitroreductase activity. The importance of the highly heterogeneous distribution of oxygen in skin requires further study, but recent investigations suggest that skin hypoxia may have important clinical ramifications including mediating cellular transformation.

[1]  S. Lahiri,et al.  Intracellular PO2 of the carotid body. , 2000, Advances in experimental medicine and biology.

[2]  G. Stevens,et al.  Radiosensitization of mouse skin by oxygen and depletion of glutathione. , 1995, International journal of radiation oncology, biology, physics.

[3]  H. Aro,et al.  Irradiation‐Induced Hypoxia in Bones and Soft Tissues: An Experimental Study , 1986, Plastic and reconstructive surgery.

[4]  C. Koch,et al.  Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers. , 1993, Biochemical pharmacology.

[5]  L. M. Cobb,et al.  Microscopic distribution of misonidazole in mouse tissues. , 1989, British Journal of Cancer.

[6]  M. Hauer-Jensen,et al.  The radiotherapeutic injury--a complex 'wound'. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  J. Koziol,et al.  Normal transcutaneous oxygen pressure in skin after radiation therapy for cancer , 1994, Cancer.

[8]  S. Hahn,et al.  Hypoxia in human intraperitoneal and extremity sarcomas. , 2001, International journal of radiation oncology, biology, physics.

[9]  D. Fraker,et al.  EF5 binding and clinical outcome in human soft tissue sarcomas. , 2006, International journal of radiation oncology, biology, physics.

[10]  C. Koch,et al.  Hypoxic Heterogeneity in Human Tumors: EF5 Binding, Vasculature, Necrosis, and Proliferation , 2001, American journal of clinical oncology.

[11]  Dao-Yi Yu,et al.  Retinal degeneration and local oxygen metabolism. , 2005, Experimental eye research.

[12]  J. Kristl,et al.  Improved skin oxygenation after benzyl nicotinate application in different carriers as measured by EPR oximetry in vivo. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[13]  L. M. Cobb,et al.  Autoradiographic study of tritium-labeled misonidazole in the mouse. , 1989, International journal of radiation oncology, biology, physics.

[14]  T. K. Hunt,et al.  Oxygen: At the Foundation of Wound Healing—Introduction , 2004, World Journal of Surgery.

[15]  P. Declerck,et al.  In vitro reductive activation of nitroimidazoles. , 1986, Biochemical pharmacology.

[16]  S. Hahn,et al.  Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ]. , 2000, Cancer research.

[17]  Peter T. Nelson,et al.  Comparative Measurements of Hypoxia in Human Brain Tumors Using Needle Electrodes and EF5 Binding , 2004, Cancer Research.

[18]  C. Koch,et al.  Chondrocytes in the endochondral growth cartilage are not hypoxic. , 1997, The American journal of physiology.

[19]  Till Acker,et al.  Cellular oxygen sensing need in CNS function: physiological and pathological implications , 2004, Journal of Experimental Biology.

[20]  Peter T. Nelson,et al.  Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors , 2004, Clinical Cancer Research.

[21]  C. Koch,et al.  2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. , 1996, Cancer research.

[22]  S M Evans,et al.  Detection of hypoxia in human squamous cell carcinoma by EF5 binding. , 2000, Cancer research.

[23]  T. Utsunomiya,et al.  The difference in chemosensitivity to antineoplastic agents of human hepatocellular carcinoma cells under normo-oxygenated or hypoxic conditions. , 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  C. Koch The Reduction Activation of Nitroimidazoles; Modification by Oxygen and other Redox-Active Molecules in Cellular Systems , 1990 .

[25]  Thomas A. Mustoe, MD, FACS,et al.  Oxygen in Wound Healing—More than a Nutrient , 2004, World Journal of Surgery.

[26]  G. Adams Hypoxia‐mediated druGS FOR RADIATION AND CHEMOTHERAPY , 1981 .

[27]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[28]  C. Koch,et al.  Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro. , 1987, Cancer research.

[29]  María Angeles Peinado,et al.  The role of free radicals in cerebral hypoxia and ischemia. , 2005, Free radical biology & medicine.

[30]  C. Koch,et al.  Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles , 2001, Cancer Chemotherapy and Pharmacology.

[31]  M. Dewhirst,et al.  Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. , 2004, Cancer cell.

[32]  G. Wilson,et al.  Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys. , 1992, International journal of radiation oncology, biology, physics.

[33]  L. Wiebe,et al.  Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. , 1992, British Journal of Cancer.

[34]  C. Koch,et al.  Permanent Anatomic Closure of the Ductus Arteriosus in Newborn Baboons: The Roles of Postnatal Constriction, Hypoxia, and Gestation , 1999, Pediatric Research.

[35]  J. Brown,et al.  Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. , 1991, International journal of radiation oncology, biology, physics.

[36]  L. M. Cobb,et al.  Distribution of pimonidazole and RSU 1069 in tumour and normal tissues. , 1990, British Journal of Cancer.

[37]  J. Pouysségur,et al.  Hypoxia: the tumor's gateway to progression along the angiogenic pathway. , 2001, Trends in cell biology.

[38]  L. M. Cobb,et al.  Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse. , 1990, International journal of radiation oncology, biology, physics.

[39]  F. Stewart,et al.  Skin sensitization by misonidazole: a demonstration of uniform mild hypoxia. , 1982, British Journal of Cancer.

[40]  C. Koch,et al.  Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. , 2002, Methods in enzymology.

[41]  E. Fuchs,et al.  Defining the Epithelial Stem Cell Niche in Skin , 2004, Science.

[42]  L. M. Cobb,et al.  NAD(P)H nitroblue tetrazolium reductase levels in apparently normoxic tissues: a histochemical study correlating enzyme activity with binding of radiolabelled misonidazole. , 1990, British Journal of Cancer.

[43]  C. Koch,et al.  Imaging hypoxia and blood flow in normal tissues. , 1997, Advances in experimental medicine and biology.

[44]  D. Ferriero,et al.  Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia–ischemia , 1999, Neuroscience.

[45]  Abels Ri Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. , 1992 .

[46]  C. Koch,et al.  Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. , 1996, The Journal of pharmacology and experimental therapeutics.

[47]  Amato J Giaccia,et al.  The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. , 2005, Cancer cell.

[48]  C. Koch,et al.  Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. , 2002, Cancer research.

[49]  C. Koch,et al.  Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.